Trial intelligence / Profile preview

QL-007 plus nucleos(t)ide analogs in chronic hepatitis B

CTR20190918Phase 2Completed

Sponsor
Qilu Pharmaceutical
Start
Sep 2019
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of QL-007 in Chronic Hepatitis B (CHB), sponsored by Qilu Pharmaceutical. Started Sep 2019; status: completed.

02

Drugs

QL-007
03

Conditions

Chronic Hepatitis B (CHB)

Beyond the preview

Go deeper on CTR20190918.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20190918.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call